Arabic Arabic English English French French German German
dark

Everest Medicines Will Participate in a Clinical Trial with Gilead and MSD to Evaluate Trodelvy® in Combination with KEYTRUDA® (pembrolizumab) in First-Line Metastatic Non-Small Cell Lung Cancer

Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), today announced it will participate in a study pursuant to a clinical trial collaboration between Gilead and MSD to evaluate the combination of the Trop-2 targeting antibody-drug conjugate (ADC) Trodelvy. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Nutriband Inc. And Kindeva Drug Delivery Sign Feasibility Agreement to Develop AVERSA(TM) Fentanyl, an Abuse Deterrent Fentanyl Patch

Next Post

Allianz unit seals reinsurance deal

Related Posts
Total
0
Share